在心力衰竭患者中,环环酸盐与聚二硫酸盐的有效性比较
Hiroki Shimada1, Kayoko Mizuno1, Koji Kawakami2
1Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshida Konoecho, Sakyoku, Kyoto, 606-8501, Japan.
Heart and vessels
|October 7, 2025
概括
与聚二硫酸盐 (CPS) 相比,聚二硫酸盐 (SZC) 在心力衰竭 (HF) 患者中没有改善存活率或心血管结果. 然而,SZC的使用与如MRA等心力衰竭药物的更好的延续有关.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 心力衰竭 (HF) 患者面临高血症风险,需要有效的降疗法.
- 环环酸盐 (SZC) 是一种结合剂,但其在高血压中对心血管的影响尚不清楚.
- 将SZC与聚二硫酸盐 (CPS) 进行比较对于优化高温管理至关重要.
研究的目的:
- 为了比较SZC与CPS对HF患者死亡率和主要心血管不良事件 (MACE) 的影响.
- 评估SZC和CPS对单个MACE成分和HF药物持续率的影响.
主要方法:
- 使用JMDC医院数据库 (2020年4月 - 2023年9月) 的回顾性队列研究.
- 包括成人HF患者开始SZC或CPS并持续至少30天.
- 基于倾向分数的治疗权重反向概率 (IPTW) 和多变量考克斯模型被采用.
主要成果:
- 在IPTW之后,主要复合结局 (全因死亡或MACE住院) 没有显著差异 (HR 1.16;95% CI 0.94-1.43).
- SZC与高血压住院的风险更高 (HR 1.36; 95% CI 1.06-1.75) 相关,但中风住院的风险更低 (HR 0.33; 95% CI 0.12-0.91).
- 矿物质皮质类受体抗剂 (MRA) 的持续性在SZC (加权OR1.39;95%CI1.11-1.75) 显著更高.
结论:
- 与HF患者的CPS相比,SZC没有显示出改善的存活率或整体心血管结果.
- SZC可能有助于延续必要的高频疗法,特别是MRAs,这在临床上具有重要意义.
- 需要进一步的研究来阐明SZC在不同高频群体中的特定益处和风险.
相关概念视频
01:22Heart Failure Drugs: Diuretics
804
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
804
01:30Heart Failure V: Medical Management
218
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
218
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
932
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
932
01:22Heart Failure Drugs: β-Blockers
770
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
770
01:22Heart Failure VI: Adjunct Therapies
255
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
255
01:29Heart Failure II: Pathophysiology
722
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
722